Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celyad's novel CAR T-cell therapy for solid malignancies.

Caroline Lonez1, Alain Hendlisz2, Leila Shaza2

  • 1Celyad, Mont-Saint-Guibert, Belgium.

Current Research in Translational Medicine
|April 8, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
Same author

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same author

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same author

From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers.

Current opinion in oncology·2026
Same author

Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.

Cancer immunology research·2026
Same author

Unraveling the sodium storage mechanism in a redox-active covalent organic framework cathode for Na-metal batteries.

Journal of materials chemistry. A·2026
Same journal

Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.

Current research in translational medicine·2026
Same journal

Allogeneic mesenchymal stem cell therapy combined with photobiomodulation for neonatal soft-tissue necrosis: A case report.

Current research in translational medicine·2026
Same journal

Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

Current research in translational medicine·2026
Same journal

Comparison of genomic response among patients receiving dendritic cell vaccines pulsed with two different cancer-associated antigens: A retrospective observational study.

Current research in translational medicine·2026
Same journal

A survey on artificial intelligence use for myeloma and lymphoma management.

Current research in translational medicine·2026
Same journal

Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.

Current research in translational medicine·2026
See all related articles
This summary is machine-generated.

Celyad

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy has shown promise in hematologic malignancies.
  • Solid tumors present unique challenges for CAR T-cell efficacy, including the tumor microenvironment.
  • Natural killer group 2D (NKG2D)-based CARs offer a distinct approach to target tumor cells.

Purpose of the Study:

  • To review the properties of CYAD-01, a novel NKG2D-based CAR therapy.
  • To discuss the potential of CYAD-01 in treating solid and hematologic tumors.
  • To explore CYAD-01's potential as a new therapeutic paradigm.

Main Methods:

  • Review of preclinical and clinical data for CYAD-01.
  • Analysis of the mechanism of action of NKG2D-based CARs.

Related Experiment Videos

  • Discussion of ongoing clinical trials in solid and hematologic tumors.

    • Main Results:

    • CYAD-01 utilizes the NKG2D receptor to target tumor cells expressing NKG2D ligands.
    • Early clinical data suggest potential activity in both solid and hematologic cancers.
    • The therapy is being evaluated in multiple ongoing clinical trials.

    Conclusions:

    • CYAD-01 represents a novel CAR T-cell therapy targeting NKG2D.
    • This approach may offer a new strategy to overcome challenges in solid tumor treatment.
    • Further clinical investigation is warranted to establish CYAD-01's therapeutic role.